Hims & Hers Has Lost Half Its Market Value in 2026 as the FDA, Novo Nordisk, and the DOJ Dismantle Its Compounded GLP-1 Business in Under Two Weeks
Hims & Hers has lost half its market value in 2026 after launching a $49 compounded semaglutide pill triggered an FDA crackdown, a Novo Nordisk lawsuit, a DOJ referral, and a forced product suspension in under two weeks.